Key terms

About MIRM

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest MIRM news

May 10 1:42am ET Mirum Pharmaceuticals: Strong Buy Recommendation Amidst Resilient Performance and Promising Clinical Prospects by TipRanks May 10 1:29am ET Positive Outlook for Mirum Pharmaceuticals with Buy Rating Amid Upcoming Catalysts and Robust Financials by TipRanks May 09 8:30am ET Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM) by TipRanks May 09 6:37am ET Buy Rating for Mirum Pharmaceuticals Amidst Strong Sales and Promising Drug Pipeline by TipRanks May 09 6:36am ET Mirum Pharmaceuticals price target lowered to $66 from $72 at JMP Securities by TipRanks May 09 5:55am ET Mirum Pharmaceuticals price target raised to $38 from $37 at Citi by TipRanks May 09 12:50am ET Analysts Are Bullish on These Healthcare Stocks: Paragon 28 (FNA), Prothena (PRTA) by TipRanks May 08 4:12pm ET Mirum Pharmaceuticals announces H1 milestones on track by TipRanks Apr 16 4:35pm ET Buy Rating Affirmed for Mirum Pharmaceuticals Amidst Strategic Positioning and Treatment Breakthroughs by TipRanks Apr 16 4:20pm ET Mirum Pharmaceuticals initiated with a Buy at Stifel by TipRanks Apr 16 6:05am ET Buy Rating Affirmed for Mirum Pharmaceuticals Amid Positive Clinical Trial Outlook by TipRanks Apr 05 1:25pm ET Mirum Pharmaceuticals participates in a conference call with JPMorgan by TipRanks Apr 05 4:55am ET Mirum Pharmaceuticals participates in a conference call with JPMorgan by TipRanks Apr 04 4:35pm ET Mirum Pharmaceuticals participates in a conference call with JPMorgan by TipRanks Apr 02 11:50am ET Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Rocket Pharmaceuticals (RCKT) by TipRanks Mar 18 8:25am ET Mirum Pharmaceuticals price target lowered to $43 from $44 at Leerink by TipRanks Mar 17 2:02am ET Mirum Pharmaceuticals’ Financial Uncertainty: FDA Approval Hurdles for Chenodal’s CTX Treatment by TipRanks Mar 14 6:25am ET Mirum Pharmaceuticals’ LIVMARLI: A Strong Buy on Expanded FDA Approval and Promising Commercial Outlook by TipRanks Mar 14 3:29am ET 3 Best Stocks to Buy Now, 3/14/2024, According to Top Analysts by TipRanks Mar 14 12:25am ET Buy Rating Affirmed for Mirum Pharmaceuticals Following FDA Approval and Positive Revenue Outlook by TipRanks Mar 13 6:00pm ET Mirum Pharmaceuticals’ Livmarli receives FDA approval by TipRanks Mar 01 10:50am ET Cantor Fitzgerald biotech analyst holds an analyst/industry conference call by TipRanks Mar 01 10:07am ET Cantor Fitzgerald biotech analyst holds an analyst/industry conference call by TipRanks Mar 01 1:16am ET Buy Rating Affirmed for Mirum Pharmaceuticals Amid Strong Q4 Performance and Optimistic 2024 Outlook by TipRanks Mar 01 1:10am ET Buy Rating Affirmed for Mirum Pharmaceuticals Amid Strong Financials and Promising Regulatory Milestones by TipRanks Feb 29 11:21am ET Mirum Pharmaceuticals price target lowered to $45 from $58 at H.C. Wainwright by TipRanks Feb 29 8:47am ET Mirum Pharmaceuticals publishes data from Livmarli analysis by TipRanks Feb 29 7:20am ET Mirum Pharmaceuticals price target raised to $69 from $64 at JMP Securities by TipRanks Feb 29 12:40am ET Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Integra Lifesciences (IART) by TipRanks Feb 28 4:14pm ET Mirum Pharmaceuticals reports Q4 revenue $69.554M, consensus $67.91M by TipRanks Feb 27 6:26am ET Buy Rating Affirmed for Mirum Pharmaceuticals on Strong Sales and Growth Prospects by TipRanks
May 02 2:33pm ET Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management by Newsfile

MIRM Financials

1-year income & revenue

Key terms

MIRM Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

MIRM Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Dave Calhoun, chief executive officer of Boeing Co., center right, on Capitol Hill in Washington, DC, US, on Wednesday, Jan. 24, 2024. The company is working to assure airline customers and the Federal Aviation Administration that its jets are safe after a January 5 accident, which involved a faulty door panel on a 737 Max 9 aircraft operated by Alaska Airlines.
Samuel Corum/Bloomberg/Getty Images
Boeing shareholders vote to approve $33 million CEO pay package
ZHANGYE, CHINA - APRIL 16, 2024 - Workers check photovoltaic panels before packing at the New Material 800MW high-efficiency photovoltaic module production line in Zhangye city, Gansu province, China, April 16, 2024.
CFOTO/Future Publishing/Getty Images
Biden’s tariffs on Chinese imports are boosting these beaten-down stocks
Traders work on the floor of the New York Stock Exchange on May 16, 2024. Wall Street is buoyed by hopes the Federal Reserve will pull back on its restrictive monetary policy after data showed inflation is beginning to ease.
Spencer Platt/Getty Images
Dow briefly tops 40,000 for first time but ends the day lower
Shoppers at a Walmart store in Secaucus, New Jersey, US, on Tuesday, March 5, 2024. Walmart is revamping more than 800 store locations and adding high-end products.
Gabby Jones/Bloomberg/Getty Images
Walmart’s business surges as shoppers hunt for low prices